Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2022-12-06 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司董事会薪酬与考核委员会工作细则（2022年12月）
Governance Information Classification · 95% confidence The document is titled '董事会薪酬与考核委员会工作细则' which translates to 'Board Remuneration and Assessment Committee Working Rules'. It details the structure, responsibilities, composition, and procedures of the board's remuneration and assessment committee. It does not contain financial statements, earnings data, or regulatory filings. It is a governance-related document outlining internal rules and governance practices related to board remuneration and assessment. Therefore, it fits best under the category of Governance Information (CGR). The document length is 2484 characters, which is relatively short but contains substantive governance content, not just an announcement or summary.
2022-12-06 Chinese
哈药集团股份有限公司董事会审计委员会工作细则（2022年12月）
Governance Information Classification · 95% confidence The document is titled '董事会审计委员会工作细则' which translates to 'Board Audit Committee Working Rules'. It details the structure, responsibilities, procedures, and regulations governing the audit committee of the board of directors. It includes references to internal and external audit supervision, internal control evaluation, audit committee meetings, and annual audit work procedures. There is no financial data, no report of financial results, no earnings information, no voting results, no management changes, no legal proceedings, no capital updates, and no announcement of a report publication. The document is a governance-related internal regulation document describing the audit committee's role and operation within the company. Therefore, it fits best under Governance Information (CGR). The document length is about 5031 characters, which is sufficient for a detailed governance document. Confidence is high as the content clearly matches governance rules and committee procedures.
2022-12-06 Chinese
哈药集团股份有限公司关于所属企业药品通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 哈药集团股份有限公司 regarding the approval of a pharmaceutical product (盐酸氟桂利嗪胶囊) passing the generic drug consistency evaluation by the National Medical Products Administration. It details the drug's background, regulatory approval, market impact, and risk warnings. The document is short (1238 characters) and serves as an official announcement of a regulatory milestone rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management changes. It is not a report publication announcement since it is the announcement itself, not about a report release. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about product approval and market impact.
2022-11-03 Chinese
哈药集团股份有限公司2022年三季度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled '2022 年第三季度报告' which translates to '2022 Third Quarter Report'. It contains detailed financial data including income statements, balance sheets, cash flow statements, and notes for the third quarter of 2022. The document explicitly states it is an unaudited quarterly report and includes comprehensive financial figures and analysis for the quarter and year-to-date periods. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is over 12,000 characters, indicating it is the full report, not just an announcement. Therefore, the correct classification is IR with high confidence. 9M 2022
2022-10-26 Chinese
哈药集团股份有限公司九届十五次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a supervisory board resolution announcement regarding the approval of the company's 2022 third quarter report. It includes the supervisory board's review and confirmation that the report complies with relevant laws and regulations. The document itself is not the quarterly report but an announcement of the supervisory board's approval and opinion on the report. The length is short (651 characters), and it does not contain actual financial data or detailed financial statements. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) as it is a compliance announcement related to the quarterly report.
2022-10-26 Chinese
哈药集团股份有限公司九届三十一次董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a board resolution announcement from Harbin Pharmaceutical Group Co., Ltd. It reports the approval of the company's 2022 third quarter report by the board of directors and mentions that the detailed report is disclosed on the Shanghai Stock Exchange website. The document itself does not contain the full third quarter financial report but rather announces the board's approval and refers readers to the full report elsewhere. Additionally, it includes a resolution about increasing the company's credit line, which is a financing update. However, the primary focus is the board meeting resolution and announcement of the quarterly report approval, not the report itself. The document length is short (807 characters), and it fits the pattern of a Regulatory Filing (RNS) as a general announcement and compliance disclosure rather than the full Interim/Quarterly Report (IR).
2022-10-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.